skip to main content
Idioma:
Resultados 1 2 next page
Refinado por: Nome da Publicação: Annals Of Oncology remover assunto: Middle Aged remover Life Sciences & Biomedicine remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients

Cals, L. ; Rixe, O. ; François, E. ; Favre, R. ; Merad, L. ; Deplanque, G. ; Laadem, A. ; Juin, P. ; Bereder, J. M. ; Bernardini, D. ; Herait, P.

Annals of oncology, 2004-07, Vol.15 (7), p.1018-1024 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível

Citações Citado por
2
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer

Thomas, AL ; Trarbach, T ; Bartel, C ; Laurent, D ; Henry, A ; Poethig, M ; Wang, J ; Masson, E ; Steward, W ; Vanhoefer, U ; Wiedenmann, B

Annals of oncology, 2007-04, Vol.18 (4), p.782-788 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível

Citações Citado por
3
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I–II study
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I–II study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I–II study

Laurent, S. ; Monsaert, E. ; Boterberg, T. ; Demols, A. ; Borbath, I. ; Polus, M. ; Hendlisz, A. ; de Hemptinne, B. ; Mahin, C. ; Scalliet, P. ; Van Laethem, J.-L. ; Peeters, M.

Annals of oncology, 2009-08, Vol.20 (8), p.1369-1374 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study

André, T. ; Blons, H. ; Mabro, M. ; Chibaudel, B. ; Bachet, J-B. ; Tournigand, C. ; Bennamoun, M. ; Artru, P. ; Nguyen, S. ; Ebenezer, C. ; Aissat, N. ; Cayre, A. ; Penault-Llorca, F. ; Laurent-Puig, P. ; de Gramont, A.

Annals of oncology, 2013-02, Vol.24 (2), p.412-419 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)
From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)
Material Type:
Artigo 		Adicionar ao Meu Espaço

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)

Couraud, S. ; Cortot, A.B. ; Greillier, L. ; Gounant, V. ; Mennecier, B. ; Girard, N. ; Besse, B. ; Brouchet, L. ; Castelnau, O. ; Frappé, P. ; Ferretti, G.R. ; Guittet, L. ; Khalil, A. ; Lefebure, P. ; Laurent, F. ; Liebart, S. ; Molinier, O. ; Quoix, E. ; Revel, M.-P. ; Stach, B. ; Souquet, P.-J. ; Thomas, P. ; Trédaniel, J. ; Lemarié, E. ; Zalcman, G. ; Barlési, F. ; Milleron, B.

Annals of oncology, 2013-03, Vol.24 (3), p.586-597 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours
Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours
Material Type:
Artigo 		Adicionar ao Meu Espaço

Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours

Cros, J. ; Sbidian, E. ; Hans, S. ; Roussel, H. ; Scotte, F. ; Tartour, E. ; Brasnu, D. ; Laurent-Puig, P. ; Bruneval, P. ; Blons, H. ; Badoual, C.

Annals of oncology, 2013-10, Vol.24 (10), p.2624-2629 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology

Borbath, I. ; Ceratti, A. ; Verslype, C. ; Demols, A. ; Delaunoit, T. ; Laurent, S. ; Deleporte, A. ; Vergauwe, P. ; Van Maanen, A. ; Sempoux, C. ; Van Cutsem, E. ; Van Laethem, J.L.

Annals of oncology, 2013-11, Vol.24 (11), p.2824-2829 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Blons, H. ; Emile, J.F. ; Le Malicot, K. ; Julié, C. ; Zaanan, A. ; Tabernero, J. ; Mini, E. ; Folprecht, G. ; Van Laethem, J.L. ; Thaler, J. ; Bridgewater, J. ; Nørgård-Petersen, L. ; Van Cutsem, E. ; Lepage, C. ; Zawadi, M.A. ; Salazar, R. ; Laurent-Puig, P. ; Taieb, J.

Annals of oncology, 2014-12, Vol.25 (12), p.2378-2385 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes
Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes

Laurent, C. ; Delas, A. ; Gaulard, P. ; Haioun, C. ; Moreau, A. ; Xerri, L. ; Traverse-Glehen, A. ; Rousset, T. ; Quintin-Roue, I. ; Petrella, T. ; Emile, J.F. ; Amara, N. ; Rochaix, P. ; Chenard-Neu, M.P. ; Tasei, A.M. ; Menet, E. ; Chomarat, H. ; Costes, V. ; Andrac-Meyer, L. ; Michiels, J.F. ; Chassagne-Clement, C. ; de Leval, L. ; Brousset, P. ; Delsol, G. ; Lamant, L.

Annals of oncology, 2016-02, Vol.27 (2), p.306-314 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

Saiag, P. ; Gutzmer, R. ; Ascierto, P.A. ; Maio, M. ; Grob, J.-J. ; Murawa, P. ; Dreno, B. ; Ross, M. ; Weber, J. ; Hauschild, A. ; Rutkowski, P. ; Testori, A. ; Levchenko, E. ; Enk, A. ; Misery, L. ; Vanden Abeele, C. ; Vojtek, I. ; Peeters, O. ; Brichard, V.G. ; Therasse, P.

Annals of oncology, 2016-10, Vol.27 (10), p.1947-1947 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 next page

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.